Yecuris Corporation Joins The Janvier Group.

January 30, 2024

Le Genest-Saint-Isle, France and Portland, Oregon, USA: Janvier Group and Yecuris Corporation today announce that they have entered into a definitive combination agreement and closed a transaction late in 2023. Yecuris Corporation will continue to operate under existing management including Rob Copenhaver as CEO, Patrick Duong as Director of Finance, and Devorah Goldman, Ph.D. as Scientific Director. Yecuris Corporation will continue doing business using its own name as a company within the Janvier Group.

“We are pleased to welcome Yecuris into the Janvier Group. With its know-how, Yecuris strengthens our in vivo and in vitro product offerings as well as our preclinical services offerings, which complements the scope of current capabilities of the Group,” says Thomas Janvier, Janvier Group CEO. “This integration implements our willingness to develop our presence in the international market, adding a Janvier Group site in the US. Yecuris strongly complements the other Janvier Group companies and will strengthen the Group’s attractiveness to our customers.”

“Joining Janvier Group gives our FRG liver-humanized mouse model products and services a larger global footprint and expands the product portfolio Yecuris can offer from our US facility,” says Rob Copenhaver, CEO at Yecuris. “From the very beginning of conversations our shared scientific orientation and priority focus on customer success were clear. Going forward, the combined company will have greater depth of capabilities to create opportunity and value for our customers and employees.” Janvier Group was advised on the transaction by Baird (Lead Advisory), EY Societe d’Avocats and Masuda Funai (Legal) and EY (FDD). Yecuris was advised on the transaction by Crosstree (Lead Advisory), Tonkon Torp (Legal) and Forvis (FDD).

About Janvier Group: As an international player in the field of biomedical research, the Janvier Group is a reference in terms of research models and preclinical services. Founded in 1960, the Janvier Group is one of the world leaders, recognized for the quality of its research models and associated services which are delivered in compliance with the standards among the highest in the world market. Historically focused on research models with its subsidiary Janvier Labs which relies on the largest and most modern production site in Europe, Janvier Group is now an established player in preclinical services with its subsidiaries in France and internationally. Today, the

Janvier Group operates throughout Europe and internationally with more than 3,500 customers.

About Yecuris: Founded in 2007 as a start-up company based on technology developed in the laboratory of Dr. Markus Grompe at Oregon Health and Science University, Yecuris has grown its proprietary FRG liver-humanized mouse model into a globally recognized name. Yecuris’ products and services help biotechnology and pharmaceutical companies active in the fields of Gene Therapy, Infectious Disease, Metabolic Disease, and Liver Disease develop next-generation medicines to treat human disease. Our singular purpose is to deliver actionable results that clients can depend on to make critical decisions in their drug development programs.

About Baird: Baird is a leading global investment bank serving the M&A, equity capital markets, capital advisory and restructuring needs of its clients throughout the United States, Europe and Asia. Since 2018, Baird has completed nearly 800 advisory transactions, representing $335 billion in transaction value, and more than 400 financings, raising $181 billion.

Baird’s Global Healthcare platform includes over 50 investment bankers, who have completed over 240 healthcare M&A and financing transactions since 2017. Baird is a leading advisor in the Pharma Services sector with transaction expertise spanning contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), pharma IT and other outsourced pharma services clients.

About Crosstree: Crosstree is a global distinguished boutique investment banking firm focused exclusively on the needs of middle-market companies within three sub-sectors of the health sciences industries: pharmaceutical services and technology, diagnostics and tools, and healthcare technology.

Since 2004, Crosstree has advised on more completed transactions in Pharma Services than any other investment bank. The firm provides clients with a full suite of advisory and capital raising services, including buy-and sell-side mergers and acquisitions advisory, private capital raising, and strategic advisory. Crosstree’s narrow industry focus provides clients deep subject matter expertise to middle-market companies and investors, with unparalleled industry insights, well-established strategic relationships across the globe and superior strategic outcomes.

From offices in Tampa, Florida, Crosstree has advised clients throughout North America, Europe, India, China, Latin America, and Australia on transactions ranging from $25 million to more than $1 billion.

Rob Copenhaver CEO, Yecuris Corporation
[email protected]

Thomas Janvier CEO, Janvier Group
[email protected]